LIMN · Company research
Liminatus Pharma, Inc. Class A Common Stock (LIMN): Valuation Analysis
Available valuation snapshots and ratios; unavailable metrics remain blank.
RESEARCH CONTEXT
Understand the numbers
Available valuation snapshots and ratios; unavailable metrics remain blank. Use period, currency, units and source fields when interpreting values.
1records availableHealthcare
Valuation Analysis data
Database-backed records only
| valuation date | price | market cap | enterprise value | pe | forward pe | peg | price sales | price book | price fcf |
|---|---|---|---|---|---|---|---|---|---|
| Oct 8, 2026 | 3.88 | $206,660,800.78 | 203643704.78 | — | — | — | — | 687.4669034502947321 | — |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.